This is a preview of subscription content, log in via an institution to check access.
Reference
Ackroyd SA, et al. Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis. Gynecologic Oncology : 6 Jun 2021. Available from: URL: http://doi.org/10.1016/j.ygyno.2021.05.038
Rights and permissions
About this article
Cite this article
Pembrolizumab + lenvatinib for certain subtypes of advanced/recurrent endometrial cancer: survival/QALY benefits at high cost. PharmacoEcon Outcomes News 881, 26 (2021). https://doi.org/10.1007/s40274-021-7822-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7822-9